Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis

Modern Rheumatology

Volumn 20, Issue 2, 2010, Pages 139-146

  Tsujimura, Shizuyo ^a   Saito, Kazuyoshi ^a   Nakayamada, Shingo ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Drug resistance; Etanercept; Lymphocytes; P glycoprotein; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; BUCILLAMINE; CD69 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLYCOPROTEIN P; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ALOPECIA; AMYLOIDOSIS; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LYMPHOCYTE ACTIVATION; NAUSEA; PANCYTOPENIA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RHEUMATOID VASCULITIS; VASCULITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LYMPHOCYTES; MIDDLE AGED; P-GLYCOPROTEIN; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 77954759857     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0247-0     Document Type: Article

References (22)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907-16.
2. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996;56:3010-20.
3. Ueda K, Cardaralli C, Gottesman MM, Pastan I. Expression of a full length cDNA for the human "MDR-1" gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA. 1987;84:3004-8.
4. Salmon SE, Dalton WS. Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. J Rheumatol Suppl. 1996;44:97-101.
5. Chen C, Pollack GM. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm Res. 1999;16:296-301.
6. Yudoh K, Matsuno H, Nakazawa F, Yonezawa T, Kimura T. Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum. 1999;42:2014-5.
7. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells. 2004;9:1265-73.
8. Tsujimura S, Saito K, Kohno K, Tanaka Y. Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4? T cells. J Biol Chem. 2006;281:38089-97.
9. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2008;67:380-8.
10. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Piel PL. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995; 38:44-8.
11. Tanaka Y, Minami Y, Mine S, Hirano H, Hu CD, Fujimoto H, et al. H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. J Immunol. 1999;163:6209-16.
12. Tanaka Y, Wake A, Horgan KJ, Murakami S, Aso M, Saito K, et al. Distinct phenotype of leukemic T cells with various tissue tropisms. J Immunol. 1997;158:3822-9.
13. Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cell. 1994;12:456-65.
14. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum. 1967;10:357- 76.
15. Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann Rheum Dis. 1985;44:817-22.
16. Marzio R, Mauël J, Betz-Corradin S. CD69 and regulation of the immune function. Immunopharmacol Immunotoxicol. 1999; 21:565-82.
17. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1676- 83.
18. Brocq O, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with antiTNF alpha. Press Med. 2002;31:1836-9.
19. vanVollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann Rheum Dis. 2003;62:1195-8.
20. vanVollenhoven R. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007;66:849-51.
21. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66:893-9.
22. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004;63:1344-6.